Cargando…
Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains
BACKGROUND: Combined antiretroviral therapy has drastically reduced mortality and morbidity of HIV-infected individuals. Nevertheless long-term toxicity and appearance of viral resistance hampers the prolonged effectiveness of combination therapy, requiring a continuous input of drugs to replace tho...
Autores principales: | Sironi, Francesca, Malnati, Mauro, Mongelli, Nicola, Cozzi, Paolo, Guzzo, Christina, Ghezzi, Silvia, Martínez-Romero, Carles, García-Sastre, Adolfo, Lusso, Paolo, Jabes, Daniela, Biswas, Priscilla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399250/ https://www.ncbi.nlm.nih.gov/pubmed/25888743 http://dx.doi.org/10.1186/s12967-015-0461-9 |
Ejemplares similares
-
The CD8-Derived Chemokine XCL1/Lymphotactin Is a Conformation-Dependent, Broad-Spectrum Inhibitor of HIV-1
por: Guzzo, Christina, et al.
Publicado: (2013) -
Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry
por: Mazzon, Michela, et al.
Publicado: (2019) -
Targeting viral entry as a strategy for broad-spectrum antivirals
por: Mazzon, Michela, et al.
Publicado: (2019) -
Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4
por: Burastero, Samuele E., et al.
Publicado: (2011) -
HIV-1 Env associates with HLA-C free-chains at the cell membrane modulating viral infectivity
por: Serena, Michela, et al.
Publicado: (2017)